MedTrace Logo

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

NCT01445626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2013-02-18

Study results available
· View outcomes & findings →

Summary

This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).

Conditions

  • Macular Edema

Interventions

DRUG

dexamethasone intravitreal implant 0.7 mg

Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445626 on ClinicalTrials.gov